Enhanced Collaboration Between UAE and China Boosts Vaccine Production Sector
In a significant step towards regional self-reliance in healthcare, CanSino Biologics Inc. is collaborating with UAE-based companies to produce its inhaled COVID-19 vaccine locally. This partnership was highlighted by Dr. Xuefeng Yu, Chairman and CEO of CanSino Biologics, at the World Local Production Forum 2025.
Dr. Yu commended the robust UAE-China relationship, particularly in healthcare, and praised the UAE's commitment to becoming a regional biotechnology hub. He expressed confidence in the continued strengthening of UAE-China collaboration, considering the UAE's strategic vision as forward-looking and positioning the country at the forefront of health innovation.
The partnership between CanSino Biologics and UAE-based companies is part of a broader strategy by the Chinese biotech firm to localize vaccine production internationally. While the exact details of the collaboration agreement or the manufacturing setup in the UAE are not fully disclosed, it is established that CanSino is engaging with UAE firms to facilitate local vaccine production and clinical trials.
This collaboration aims to enhance regional vaccine availability and production capacity, aligning with CanSino’s expansion of vaccine-related production capacity to meet increasing global demands. However, no direct details of production facilities, technology transfer, or exact partner company names in the UAE were found in the available sources.
Dr. Yu emphasized the importance of partnerships with local firms for boosting domestic manufacturing capabilities and fostering innovation and sustainability in the biotech sector. He also mentioned that these collaborations support public health resilience and reinforce the UAE’s growing stature as a biotech leader in the Middle East.
This evolving strategic partnership between CanSino Biologics and UAE-based companies is well-positioned to deliver lasting advantages for both nations. The COVID-19 pandemic has served as a pivotal moment of cooperation between the UAE and China, deepening bilateral trust and shared benefits. Dr. Yu considers this partnership as a testament to this growing relationship and a promising step towards a healthier and more resilient future.
- Dr. Yu highlights the UAE's commitment to becoming a regional biotechnology hub as part of the UAE-China collaboration in health innovation, bolstered by technology and innovation within the health-and-wellness sector.
- This strategic partnership between CanSino Biologics and UAE-based companies, regarding local vaccine production, represents a significant stride in the expansion of vaccine-related production capacity aimed at meeting global demands and fostering sustainability in the industry.
- Marked by financial and business investments, the collaboration agreement between CanSino Biologics and UAE firms is an integral component of CanSino's broader strategy for localizing vaccine production around the world.
- By boosting domestic manufacturing capabilities through local collaborations in the biotech sector, CanSino Biologics aims to increase public health resilience, reinforcing the UAE's growing stature as a biotech leader in the Middle East and contributing to regional self-reliance in healthcare.
- The partnership between CanSino Biologics and UAE-based companies is poised to yield enduring benefits for both nations, capitalizing on the COVID-19 pandemic as a catalyst for strengthening bilateral ties, fostering innovation, and promoting sustainability in the industry and across the region.
